Alfred B. Nobel Section of Hematology and Medical Oncology, Boston University Chobanian and Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
Bioessays. 2024 Jan;46(1):e2300143. doi: 10.1002/bies.202300143. Epub 2023 Nov 20.
Modeling metastasis in animal systems has been an important focus for developing cancer therapeutics. Xenopus laevis is a well-established model, known for its use in identifying genetic mechanisms underlying diseases and disorders in humans. Prior literature has suggested that the drug, ivermectin, can be used in Xenopus to induce melanocytes to convert into a metastatic melanoma-like state, and thus could be ideal for testing possible melanoma therapies in vivo. However, there are notable inconsistencies between ivermectin studies in Xenopus and the application of ivermectin in mammalian systems, that are relevant to cancer and melanoma research. In this review, we examine the ivermectin-induced phenotypes in Xenopus, and we explore the current uses of ivermectin in human research. We conclude that while ivermectin may be a useful drug for many biomedical purposes, it is not ideal to induce a metastatic melanocyte phenotype in Xenopus for testing the effects of potential melanoma therapeutics.
在动物系统中模拟转移一直是开发癌症治疗方法的一个重要重点。非洲爪蟾是一种成熟的模型,因其用于鉴定人类疾病和疾病的遗传机制而闻名。先前的文献表明,药物伊维菌素可用于非洲爪蟾中诱导黑素细胞转化为转移性黑色素瘤样状态,因此非常适合体内测试可能的黑色素瘤治疗方法。然而,伊维菌素在非洲爪蟾和伊维菌素在哺乳动物系统中的应用之间存在显著的不一致,这与癌症和黑色素瘤研究有关。在这篇综述中,我们检查了伊维菌素在非洲爪蟾中诱导的表型,并探讨了伊维菌素在人类研究中的当前用途。我们的结论是,虽然伊维菌素可能对许多生物医学目的有用,但它不是诱导非洲爪蟾中转移性黑素细胞表型的理想药物,无法用于测试潜在黑色素瘤治疗方法的效果。